DuoCort Pharma and Recipharm start collaboration
Recipharm will scale-up manufacture of DuoCort treatment for Addison’s disease
DuoCort Pharma has concluded an agreement with Swedish contract manufacturer Recipharm under which Recipharm will scale-up production of the drug developer’s treatment for Addison’s disease to commercial scale.
DuoCort Pharma, also based in Sweden, is preparing for market entry of its orphan drug for the treatment of adrenal insufficiency, also known as Addison’s disease.
Although cortisol replacement therapy for adrenal insufficiency has been around for a long time, several studies have recorded premature death, impaired quality of life, increased risk of cardiovascular diseases and decreased bone mineral density in these patients. Existing replacement therapies, unable to mimic cortisol’s normal diurnal release profiles, are said to be the likely cause of these outcomes.
DuoCort Pharma’s new treatment has a physiological release profile that mimics the body’s natural release of cortisol, thereby improving treatment outcomes, the company says.
‘We are very pleased to be working with an organisation of Recipharm’s calibre to scale-up our tablet manufacturing process. It is a real endorsement of the quality and commercial potential of our drug development that Recipharm has chosen to co-invest in this with us,’ said Maria Forss, chief executive of DuoCort Pharma.
